AbCellera said Monday that its experimental antibody drug ABCL635 reduced the frequency and severity of hot flashes in a mid-stage trial.
The results are significant because they offer a potential non-hormonal alternative for women suffering from moderate-to-severe vasomotor symptoms associated with menopause.
The Phase 2 clinical trial enrolled 92 participants [4]. According to the company, the antibody treatment lowered the occurrence of hot flashes, which are a primary symptom of the menopausal transition. The drug is designed to target these symptoms without the use of hormones, addressing a growing market for non-hormonal menopause therapies.
Investor reaction to the announcement was immediate and positive. Share prices rose in pre-market trading on Monday. Reports on the exact magnitude of the surge varied, with some sources citing a 24% increase [1] and others noting a rise of nearly 35% [2]. MarketWatch said the shares jumped 38% to reach $9.58 [3].
AbCellera is a clinical-stage biotechnology company that specializes in antibody discovery. The success of ABCL635 represents a key milestone in the company's pipeline as it seeks to move the treatment toward later-stage testing and eventual regulatory approval.
While the trial results are promising, the drug remains experimental. The company will need to conduct larger Phase 3 trials to further confirm safety, and efficacy across a broader population before the treatment can be made available to the public.
“ABCL635 significantly reduced the frequency and severity of hot flashes”
The success of a non-hormonal antibody treatment for menopause addresses a significant gap in women's healthcare, as many patients cannot or choose not to use hormone replacement therapy. For AbCellera, these results validate its antibody discovery platform and signal a shift toward high-demand therapeutic markets, though the path to commercialization still requires rigorous late-stage testing.
